Analyst predicts Dendreon bankruptcy; Sinovac begins H7N9 vax production;

> An analyst has set a $0 stock price target for cancer vaccine maker Dendreon ($DNDN). The target is based on a belief that the firm's debt and weak sales are pushing it toward bankruptcy. Feature

> Beijing-based Sinovac Biotech has completed preliminary work on the manufacturing of an H7N9 vaccine. News

> Northwestern Medical has joined a Phase II trial investigating a personalized brain tumor vaccine given in combination with Avastin. Release

> Tanzania has seen no serious side effects after administering 11,000 HPV vaccines. Article

> The U.K. advertising watchdog has criticized a clinic's measles vaccine promotion. Item

> India has reportedly resolved its yellow fever vaccine shortage. Piece

> The H1N1 influenza virus has killed 35 people in India in 2013. News

> Inovio Pharmaceuticals ($INO) has reported positive preclinical data for its malaria vaccine. Article

> Arbovax is seeking VC funding to support a clinical trial of a dengue fever vaccine. Piece

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

As a new coronavirus spreads, vaccine researchers have started work on candidates against the virus—and one could enter the clinic in a few months.

Merck's HPV vaccine Gardasil is delivering blockbuster sales as demand surges. But high demand has caused somewhat of a supply constraint.